Sonoma Pharmaceuticals, Inc. / Fundamentals
Income statement
- Net revenue
€12.85M - Cost of goods sold
€8.00M - Gross profit
€4.84M - SG&A expenses
€6.30M - R&D expenses
€1.67M - EBITDA
-€3.04M - D&A
€116.31K - EBIT
-€3.13M - Interest expenses
€0.00 - EBT
-€2.72M - Tax expenses
€347.20K - Net income
-€3.06M
Cash flow statement
- Net deferred tax
€282.59K - Non-cash items
€427.33K - Changes in working capital
-€191.26K - Operating cash flow
-€1.03M - Capex
€155.94K - Other investing cash flow
€0.00 - Net investing cash flow
-€155.94K - Total cash dividends paid
€0.00 - Issuance of common stock
€2.03M - Debt repayment
-€315.33K - Other financing cash flow
€299.82K - Net financing cash flow
€2.01M - Foreign exchange effects
€44.80K - Net change in cash
€875.33K - Cash at end of period
€3.11M - Free cash flow
-€870.16K
Balance sheet
- Cash and cash equivalents
€3.11M - Cash and short-term investments
€3.11M - Total receivables
€2.24M - Inventory
€3.28M - Other current assets
€2.67M - Total current assets
€11.29M - Property, plant & equipment
€721.12K - Goodwill
€0.00 - Intangible assets
€0.00 - Long-term investments
€0.00 - Other non-current assets
€89.60K - Total non-current assets
€1.28M - Total assets
€12.57M - Accounts payable
€1.76M - Short-term debt
€202.46K - Other current liabilities
-€2.94M - Total current liabilities
€4.18M - Long-term debt
€758.16K - Deferred tax liabilities
€0.00 - Other non-current liabilities
€4.52M - Total non-current liabilities
€4.90M - Total liabilities
€9.08M - Common stock
€0.00 - Retained earnings
-€171.49M - Other equity
-€3.08M - Total equity
€3.49M - Total liabilities and shareholders' equity
€12.57M
Company information
- Market capitalization
€4.02M - Employees
10 - Enterprise Value
€215.04K
Company ratios
- Gross margin
-
37.7% Much better than peer group: -14,929.8% - EBITDA margin
-
-23.7% Much better than peer group: -31,904.0% - EBIT margin
-
-24.4% Much better than peer group: -30,383.0% - EBT margin
-
-21.1% Much better than peer group: -39,145.0% - Net margin
-
-23.8% Much better than peer group: -24,614.1% - ROE
-
-87.6% Much better than peer group: -11,562.9% - ROA
-
-24.4% Much better than peer group: -615.1% - Asset turnover
-
102.2% Much better than peer group: 74.4% - FCF margin
-
-9.2% Much better than peer group: -13,823.9% - FCF yield
-29.4% - Efficiency ratio
123.7% - Net sales per employee
-
€1.28M - Net income per employee
-
-€306.28K